Sector News

UnitedHealth adds new C-suite member from Lockheed Martin

November 14, 2019
Life sciences

UnitedHealth Group Inc. has hired Patricia Lewis as its new chief human resources officer. She’ll serve in the office of the chief executive, the company said in an email. She’s replacing D. Ellen Wilson, who is retiring.

Previously, Lewis served in the same role at Lockheed Martin Corp. She’s also worked in human resources for IBM and DuPont.

At Lockheed Martin, Lewis had success starting a number of talent initiatives, including the STEM Scholarship Program and the Program Management Talent Initiative, with the goal of increasing the presence of traditionally underrepresented groups in STEM.

Lewis was recently featured in Politco’s “Women Rule” newsletter under the heading “Wisdom of the Week.” Her wisdom read, in part, “Bold leaders consistently demonstrate courage. Being courageous means taking risks even if you are faced with an uncertain outcome.”

UnitedHealth is Minnesota’s largest public company. In 2018, it had an income of $11.99 billion on $229.48 billion in sales. It employs 18,500 people in Minnesota alone, according to Business Journal research.

By: Carrigan Miller

Source: bizjournals.com

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach